Nephrology Department of Guilin 181st Hospital, Guangxi Key Laboratory of Metabolic Diseases Research, 541002, Guilin, Guangxi, China.
Clin Immunol. 2013 Aug;148(2):186-97. doi: 10.1016/j.clim.2013.05.014. Epub 2013 May 30.
Systemic lupus erythematosus (SLE) is an autoimmune disease that is characterized by multi-organ involvement leading to significant morbidity and mortality in predominantly young women. The underlying pathogenesis involves the emergence of autoreactive T and B lymphocytes, production of autoantibodies, formation and deposition of immune complexes in various tissues leading to inflammation and organ damage. Recently, growing evidence suggests that the functions of hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs) are disrupted in SLE pathology. And HSC or MSC transplantation (HSCT/MSCT) can offer an effective and safe therapy for the severe SLE patients, resulting in disease clinical remission and improvement of organ dysfunction. In this article, we provide a brief overview of current research of autologous or allogeneic HSCT/MSCT in SLE and describe our current understanding of the mechanisms by which it plays a part in treating SLE, for better understanding of the pathogenesis, diagnosis and treatment for SLE.
系统性红斑狼疮（SLE）是一种自身免疫性疾病，其特征是多器官受累，主要发生在年轻女性，导致发病率和死亡率显著增加。其发病机制涉及自身反应性 T 和 B 淋巴细胞的出现、自身抗体的产生、免疫复合物在各种组织中的形成和沉积，导致炎症和器官损伤。最近，越来越多的证据表明，SLE 病理中造血干细胞（HSCs）和间充质干细胞（MSCs）的功能受到破坏。HSC 或 MSC 移植（HSCT/MSCT）可为严重 SLE 患者提供一种有效且安全的治疗方法，导致疾病临床缓解和器官功能改善。本文简要概述了自体或同种异体 HSCT/MSCT 在 SLE 中的研究现状，并描述了我们目前对其治疗 SLE 作用机制的理解，以更好地了解 SLE 的发病机制、诊断和治疗。
